Kim, Sung-Bae <br/><br/>
Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer.  [electronic resource] 

 -  International journal of cancer  Nov 2016 
 - 2336-42 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1097-0215 
<br/><br/><label>Standard No.: </label>10.1002/ijc.30276  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Ado-Trastuzumab Emtansine<br/>Antibodies, Monoclonal, Humanized--therapeutic use<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Biomarkers, Tumor<br/>Breast Neoplasms--drug therapy<br/>Capecitabine--administration & dosage<br/>Class I Phosphatidylinositol 3-Kinases<br/>Female<br/>Humans<br/>Kaplan-Meier Estimate<br/>Lapatinib<br/>Maytansine--analogs & derivatives<br/>Phosphatidylinositol 3-Kinases--metabolism<br/>Quinazolines--administration & dosage<br/>Receptor, ErbB-2--metabolism<br/>Trastuzumab